Born from Billions of Data points Using AI and in Collaboration with World -Leading Cancer Researchers

Our Story

“Born from billions of data points using AI and in collaboration with world-class cancer researchers”
Starlight Therapeutic is an emerging precision oncology company focused solely on CNS (central nervous system) cancers, primarily brain cancers, which comprise a large and growing market globally. 

It is estimated that there are over 120 subtypes of CNS cancers that have a devastating impact on adult and pediatric populations. Most of these CNS cancers do not have effective therapies and current treatment relies on a combination of surgery, radiotherapy, and chemotherapy. There is a significant need for new therapeutic options to improve patient outcomes. Starlight is developing our lead drug candidate, known as STAR-001, for some of the most unaddressed brain cancers.

Starlight’s Focus

CNS cancers are one of the leading causes of morbidity affecting adults, children, and the elderly with characteristically high mortality and disability rates.

Glioblastoma

Glioblastoma (GBM) is the most common malignant primary brain tumor accounting for approximately 50% cases of all gliomas...

Brain metastases

Brain metastases occur when cancer spreads from its primary site of origin to the brain. Brain metastases is the most common type of brain cancer...

Pediatric CNS cancers

The American Cancer Society estimates that more than 4,000 CNS tumors are diagnosed each year in children and adolescents making primary CNS tumors...

STAR-001 Has Multi-Billion Market Potential In CNS Cancers

Annual $5-6 billion (USD) Estimated Market Potential
Glioblastoma
$1.5-2 Billion*
Annual US Cases 13K
Other Gliomas
$1.2 Billion*
Annual US Cases 22K
Brain Metastases
$3 Billion*
Annual US Cases 100K
Other Gliomas
$0.1 Billion*
Annual US Cases 4k

Highlights of STAR-001

Granted with orphan and rare pediatric disease designations
CNS indications being pursued that have limited or no effective therapies
Excellent blood brain barrier permeability
Nanomolar potency is superior to current agents
Multiple adult and pediatric CNS clinical trials planned in multiple indications
Granted with orphan and rare pediatric disease designations
CNS indications being pursued that have limited or no effective therapies
Nanomolar potency is superior to current agents
Multiple adult and pediatric CNS clinical trials planned in multiple indications
Excellent blood brain barrier permeability

Precision Targeting for Glioblastoma

STAR-001 exhibits nanomolar potency in intracranial cell-derived xenograft (CDX) models of glioblastoma (GBM), where several rounds of treatment with STAR-001 induced significant tumor regression at nanomolar levels.
MGMT Negative
MGMT Positive
11310
MGMT Positive
Mayo39- TMZR
LN18
Our portfolio of opportunities and pipeline in CNS cancers has grown five-fold and includes multiple indications lacking any accepted standard-of-care. The formation of Starlight allows Lantern to put extreme focus on advancing STAR-001 through targeted clinical trials and dedicate increased time, resources, and personnel to progress one of the most promising drug candidates for CNS cancer patients in decades.
Panna Sharma
President and CEO of Lantern Pharma
Our portfolio of opportunities and pipeline in CNS cancers has grown five-fold and includes multiple indications lacking any accepted standard-of-care. The formation of Starlight allows Lantern to put extreme focus on advancing STAR-001 through targeted clinical trials and dedicate increased time, resources, and personnel to progress one of the most promising drug candidates for CNS cancer patients in decades.
Panna Sharma
President and CEO of Lantern Pharma
Our portfolio of opportunities and pipeline in CNS cancers has grown five-fold and includes multiple indications lacking any accepted standard-of-care. The formation of Starlight allows Lantern to put extreme focus on advancing STAR-001 through targeted clinical trials and dedicate increased time, resources, and personnel to progress one of the most promising drug candidates for CNS cancer patients in decades.
Panna Sharma
President and CEO of Lantern Pharma
Our portfolio of opportunities and pipeline in CNS cancers has grown five-fold and includes multiple indications lacking any accepted standard-of-care. The formation of Starlight allows Lantern to put extreme focus on advancing STAR-001 through targeted clinical trials and dedicate increased time, resources, and personnel to progress one of the most promising drug candidates for CNS cancer patients in decades.
Panna Sharma
President and CEO of Lantern Pharma

Lead Candidate STAR-001's Portfolio of Adult and Pediatric CNS Cancer Indications

  • Orphan Drug Designation*
  • Rare Pediatric Disease Designation
  • Rare Pediatric Disease Designation**
  • Multiple GBM patients have been enrolled in the ongoing phase 1a being conducted by Lantern Pharma***
  • The MTD from the ongoing Phase 1A LP-184 clinical trial is expected to support the later expansion to brain metastases****

Get in Touch

Contact and Support Information
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.